1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Huaren Pharmaceutical Co., Ltd.

Huaren Pharmaceutical Co., Ltd.

300110.SZ
Huaren Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
2.57
CNY
-0.07
- -
3.04BMarket Cap
Huaren Pharmaceutical Co., Ltd.
300110.SZ
(Shenzhen Stock Exchange)

Recent

price

2.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.37
0.37
0.5
0.79
0.76
0.96
1.03
1.33
1.2
1.25
1.11
1.32
1.37
1.38
1.14
1.12
1.02
Revenue per Share
0.08
0.08
0.09
0.11
0.05
0.02
0.02
0.04
0.03
0.04
0.08
0.11
0.15
0.16
-1.16
-0.39
-1.19
Basic EPS, GAAP
0.01
-0.16
-0.15
-0.17
-0.16
-0.12
0.01
0.13
0.18
0.24
-0.06
-0.51
0.15
0.22
0.25
0.29
-0.03
Free Cash Flow per Basic Share
0.01
- -
0.01
0.02
0.07
0.08
0.04
0.05
0.05
0.05
0.02
0.06
0.08
0.07
0.07
0.04
0.06
Dividend per Share
0.44
0.44
0.47
0.79
0.91
0.95
0.91
1.4
1.38
1.36
1.41
1.49
1.63
1.76
0.58
0.19
0.61
Book Value per Share
1.15
1.03
1.07
1.2
1.11
1.13
1.13
1.42
1.82
1.8
1.6
1.05
1.21
1.37
0.28
0.35
0.33
Tangible Book Value per Share
917
1,104
1,134
1,102
1,209
1,148
1,211
985
1,151
1,169
1,183
1,185
1,182
1,182
1,182
1,182
1,179
Basic Weighted Avg Shares
338
405
562
867
917
1,106
1,249
1,312
1,384
1,462
1,317
1,561
1,619
1,636
1,353
1,321
1,206
Sales/Revenue/Turnover
28.09
22.91
21.39
20.12
12.02
9.25
8.14
11.11
7.79
11.03
13.38
19.69
19.01
18.7
11.24
12.71
8.39
Operating Margin (%)
31
33
42
86
97
115
123
123
116
116
113
135
150
127
118
108
- -
Depreciation Expense
76
88
97
122
56
23
24
38
39
42
95
130
181
188
-1,368
-463
-1,404
Net Income, GAAP
17.12
15.41
16.72
15.23
11.96
8.79
17.12
27.43
14
33
13.21
10.79
11.93
16.09
- -
- -
30.3
Effective Tax Rate (%)
22.56
21.6
17.19
14.01
6.13
2.07
1.92
2.86
2.8
2.88
7.19
8.35
11.16
11.49
-101.13
-35.03
-116.49
Profit Margin (%)
688
600
171
117
-57
-117
5
112
770
886
541
517
700
1,275
-362
-481
-415
Working Capital
- -
- -
15
15
7
30
29
63
42
25
- -
231
353
837
464
271
386
LT Debt
1,104
1,192
1,339
1,459
1,480
1,440
1,526
1,548
2,242
2,248
2,330
2,443
2,600
2,766
1,374
909
1,413
Total Equity
9.29
6.82
7.25
8
4.36
3.92
3.51
4.38
3.46
4.14
6.34
8.09
6.29
5.85
- -
- -
4.19
Return on Invested Capital (%)
18.29
20.22
15.73
12.06
5.2
3.8
3.27
2.74
3.01
2.55
4.93
5.96
6.08
5.89
- -
- -
-31.1
Return on Capital (%)
22.4
19.82
19.08
17.28
5.67
2.09
2.19
3.03
2.62
2.65
5.82
7.59
9.78
9.39
-99.03
-102.69
-98.57
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,117
1,215
1,116
LT Borrowings
464
393
386
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,182
1,182
1,182
Market Capitalization
4,160
3,642
3,807

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,185
1,170
1,169
Cash, Cash Equivalents & STI
164
182
211
Accounts Receivable, Net
526
527
513
Inventories
318
281
279
Total Current Liabilities
1,547
1,624
1,584
Payables & Accruals
- -
- -
- -
ST Debt
1,117
1,215
1,116
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.03%
-13.3%
-33.83%
Free Cash Flow
147.26%
146.14%
14.64%
Net Income, GAAP
-61.55%
-162.67%
-66.17%
Sales/Revenue/Turnover
2.29%
0.74%
-2.34%
Total Cash Common Dividend
9.67%
36.96%
-46.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
407
365
302
280
1,353
2025
303
320
345
- -
1,321
2026
310
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
-1.16
2025
0.01
- -
- -
- -
-0.39
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.07
2025
0.01
- -
- -
- -
0.04
2026
0.01
- -
- -
- -
- -
Similar Companies
Koninklijke Philips N.V. (PHG)
Jiangsu Hanvo Safety Product Co., Ltd. (300952.SZ)
Gentian Diagnostics AS (GENT.OL)
Seers (458870.KQ)
Edap Tms S.a. (EDAP)
Coloplast A/S (CBHD.DE)
Business
Huaren Pharmaceutical Co., Ltd. is a China-based pharmaceutical and health industry group established in May 1998 and headquartered in Qingdao, Shandong Province. The company integrates research and development, production, and sales, focusing on pharmaceutical preparations, active pharmaceutical ingredients (APIs), medical devices, and pharmaceutical packaging materials. Its core product portfolio includes small-volume injections, large-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, tablets, capsules, powders, granules, health products, and supporting drug packaging materials. The company operates five production bases located in Qingdao, Rizhao, Xiaogan, Pubei, and Hefei, with a total production capacity of approximately 950 million bags/bottles annually. Huaren Pharmaceutical's key therapeutic focuses include nephrology, respiratory diseases, psychotropic and narcotic drug treatments, fine anesthesia, and large-volume infusion preparations. It serves domestic and international markets including Europe, Southeast Asia, and the Middle East. Huaren Pharmaceutical is also a designated emergency reserve infusion manufacturer in Shandong Province. Recent major developments include the company's strategic emphasis on innovation and expanding its pharmaceutical health industry layout through independent research and collaborative innovation, continuing to increase R&D investment, and enriching its product lines. It underwent a shareholding restructure in 2019, with the management committee of Xi'an Qujiang New Area becoming the actual controller. The company actively responds to China's "Healthy China" strategy to grow into a comprehensive pharmaceutical and health group that integrates APIs, preparations, medical devices, and pharmaceutical packaging. In addition, Huaren Pharmaceutical and its wholly owned subsidiaries, including Guangxi Yuyuan Pharmaceutical Co., Ltd., continue expanding their operational footprint. The company keeps aligning with regulatory standards such as new GMP certifications across its production lines to maintain quality and compliance. Chairman Yang Xiaodong has recently increased his shareholdings, reflecting management confidence in the company's prospects. Overall, Huaren Pharmaceutical Co., Ltd. operates as a modern pharmaceutical group providing a broad spectrum of pharmaceutical products and medical devices with ongoing strategic investments in innovation, production capacity expansions, and market development across China and international regions.